Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada's Drug Agency's assessment and reimbursement recommendation for TTFields therapy in glioblastoma. “Glioblastoma is one of the most aggressive cancers, and treatment options.

Business Wire • 13 hours ago

Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 19, 2026

Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer

NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.

Zacks Investment Research • Feb 17, 2026

What's Happening With NovoCure Stock?

NovoCure stock (NVCR) is up over 30% following the FDA's approval of its Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment in almost 30 years.

Forbes • Feb 12, 2026

NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching

NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase 2 PANOVA-4 trial in 1st-line metastatic pancreatic cancer; topline data is expected in Q1 2026. Full-year 2025 revenues grew 8% year-over-year to $655.4 million, supported by 4,620 active TTFields patients globally and strong U.S. sales momentum.

Seeking Alpha • Feb 12, 2026

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.

Barrons • Feb 12, 2026

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

The Swiss biopharmaceutical company's shares surged in after-hours trading after it said the FDA approved its Optune Pax product.

WSJ • Feb 11, 2026

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. “In the Phase 3 PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies. It also s.

Business Wire • Feb 11, 2026

NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on th.

Business Wire • Jan 12, 2026